Detection of Driver and Subclonal Mutations in Myelofibrosis: Clinical Impact on Pharmacologic and Transplant-Based Treatment Strategies

The presence of molecular markers might offer the possibility to evaluate the depth of remission and to monitor minimal residual disease after transplantation.

 Expert Rev Hematol

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.